| 
| ||||||||||||||||||
- Description
- Disease & phenotype
- Genes & alleles
- Genotyping
- Health & care
- References
- Pricing & purchasing
- Terms of use
Description
The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.
Strain Information
Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System +/+ sibling x Hemizygote (Female x Male) 24-APR-08 Species laboratory mouse Background Strain C57BL/6J Donor Strain (C57BL/6 x BALB)F2 H2 Haplotype b Generation N16F?N17p (09-NOV-05)
Generation DefinitionsDonating Investigator Dr. Matthais von Herrath, La Jolla Institute for Allergy and Immun Appearance
black
Related Genotype: a/aDescription
Transgenic mice were created with the Lymphocytic choriomeningitis virus (LCMV) glycoprotein(GP) or nucleoprotein (NP) under the control of the rat insulin promoter. Ins2-GP expression was determined only in the pancreas by RT-PCR (von Herrath et al 1994). Tg(Ins2-GP)34-20Olds untreated mice rarely develop insulin-dependent diabetes mellitus (IDDM). When challenged with LCMV they develop IDDM. The B6.C -Tg(Ins2-GP)34-20Olds mice (H2b) exhibit a rapid (10-14 days) onset of IDDM compared to C.B6-Tg(Ins2-NP)25-3Olds mice (H2d) (10-21 days) or B6.C -Tg(Ins2-NP)25-3Olds mice (H2b) (30-120 days) (Oldstone et al.,1991; von Herrath et al.,1994). Thymic expression of nucleoprotein has been shown to be responsible for this delayed onset of IDDM. Thymi from newborn B6.C -Tg(Ins2-GP)34-20Olds transplanted into nude hosts produce a primary CTL response when challenged with LCMV. CD8 T cells are required for IDDM development in both glycoprotein and nucleoprotein transgenic mice, as is interferon gamma. In interferon gamma deficient transgenics stimulated with LCMV, CTLs were present in the pancreas and around the islets of Langerhans, but did not infiltrate the islets. Additionally, nucleoprotein transgenic animals require the presence of CD4 T cells. (von Herrath, et al, 1994 and 1997)A singledose injection of anti CD80, anti CD86 or anti CD80/anti CD86 antibodies does not prevent LCMV induced diabetes in either the GP or NP transgenic mice. LCMV challenged GP transgenic mice are partially protected from diabetes by anti CD80 antibodies and completely protected by anti CD86 or anti CD80/CD86 antibodies injected daily for 14 days. However, LCMV challenged NP transgenic mice have accelerated diabetes onset when treated with anti CD80/CD86 antibodies injected daily for 14 days. LCMV induced diabetes is prevented in NP and GP transgenic mice treated with anti TNFRSF5 when treated within a defined time window. Splenocytes from these protected mice adoptively transferred disease resistance to LCMV- challenged pre diabetic GP transgenic mice. The cells thatconfer protection express ITGAX5, NK1.1 and DX5. The spleens of anti TNFRSF5 protected mice have an increased population of ITGAX5 expressing cells. When this population of cells is further fractionated into ITGAX5+, DX5+ cells, the recipient mice acquire protection from diabetes. (Homann et al., 2002)
Development
B6.C-Tg(Ins2-GP)34-20Olds/MvhJ expresses the lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) under control of the rat insulin promoter, (Ins2, commonly designated RIP). The transgene was first inserted by Oldstone, et al (1991) into C57BL/6 (H2b) x Balb/WEHI (H2d) F2 oocytes. Line 34-20, maintained by Herrath et al., (1994, 2000) has been backcrossed to C57BL/6 (H2b) for at least 10 generations. In 2005 this strain arrived at The Jackson Laboratory and is maintained Tg/? x Tg/?.
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying other alleles of Ins2
View Strains carrying other alleles of Ins2 (46 strains)
Phenotype
Phenotype Information
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Diabetes Mellitus, Insulin-Dependent; IDDM
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Tg(Ins2-GP)34-20Olds/0
involves: BALB/c * C57BL/6
- homeostasis/metabolism phenotype
- decreased circulating insulin level
- hypoinsulinemia is exhibited by transgenic mice accompanying increased glucose levels and islet infiltration (MGI Ref ID J:81287)
- increased circulating glucose level
- mice are considered diabetic after a blood glucose measure of >300 mg/dl (MGI Ref ID J:81287)
- immune system phenotype
- abnormal lymphocyte physiology
- on a B6 background, transgenic mice cannot exhibit a primary CTL response (MGI Ref ID J:81287)
- abnormal T cell physiology
- depletion of CD8+ lymphocytes with a monoclonal antibody inhibited development of diabetes (MGI Ref ID J:81287)
- increased susceptibility to autoimmune diabetes
- mice rapidly develop diabetes (glucose levels >300 mg/dl) 10-14 days after viral (LCMV) challenge (MGI Ref ID J:81287)
- endocrine/exocrine gland phenotype
- abnormal pancreatic islet morphology
- mononuclear cells infiltrate the islets of transgenic mice 5-10 days after viral innoculation (MGI Ref ID J:81287)
- absent pancreatic beta cells
- no beta cells are detected at 14 days after LCMV infection (MGI Ref ID J:81287)
This mouse can be used to support research in many areas including:
Diabetes and Obesity Research
Type 1 Diabetes (IDDM)
Immunology, Inflammation and Autoimmunity Research
Autoimmunity
Type 1 Diabetes
Research Tools
Diabetes and Obesity Research
Genes & Alleles
Gene & Allele Information provided by MGI
| Allele Symbol | Tg(Ins2-GP)34-20Olds | ||
|---|---|---|---|
| Allele Name | transgene insertion 34-20, Michael BA Oldstone, MD | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | LCMV GP; RIP GP H2b; RIP GP34-20; RIP-GP34-20; RIP-LCMV GP; | ||
| Mutation Made By | Dr. Michael Oldstone, The Scripps Research Institute | ||
| Strain of Origin | (C57BL/6 x BALB/Wehi)F2 | ||
| Expressed Gene | LCMV-GP, lymphocytic choriomeningitis virus glycoprotein, | ||
| Promoter | Ins2, insulin 2, rat | ||
| Molecular Note | This transgene encodes the glycoprotein (GP) from Armstrong's clone of the lymphocytic choriomeningitis virus (LCMV) regulated by the rat insulin promoter. Upstream of the GP cDNA are 660 base pairs of regulatory elements in addition to the rat insulin promoter. Downstream of the GP c-DNA is the SV40 small T-antigen intron and late polyadenylation signal. RT-PCR analysis demonstrated that the transcript was expressed in the pancreas but not the thymus, spleen, liver, kidney, heart, muscle or lung. [MGI Ref ID J:81287] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(Ins2-GP)34-20Olds, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
References
References provided by MGI
Selected Reference(s)
Oldstone MB; Nerenberg M; Southern P; Price J; Lewicki H. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65(2):319-31. [PubMed: 1901765] [MGI Ref ID J:81284]
Additional References
Tg(Ins2-GP)34-20Olds relatedBresson D; von Herrath MG. 2011. Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. Clin Exp Immunol 163(3):375-80. [PubMed: 21235534] [MGI Ref ID J:169310]
Filippi CM; Juedes AE; Oldham JE; Ling E; Togher L; Peng Y; Flavell RA; von Herrath MG. 2008. Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes 57(10):2684-92. [PubMed: 18689691] [MGI Ref ID J:142144]
Hall HT; Wilhelm MT; Saibil SD; Mak TW; Flavell RA; Ohashi PS. 2008. RIP2 contributes to Nod signaling but is not essential for T cell proliferation, T helper differentiation or TLR responses. Eur J Immunol 38(1):64-72. [PubMed: 18085666] [MGI Ref ID J:130818]
Holz A; Bot A; Coon B; Wolfe T; Grusby MJ; von Herrath MG. 1999. Disruption of the STAT4 signaling pathway protects from autoimmune diabetes while retaining antiviral immune competence. J Immunol 163(10):5374-82. [PubMed: 10553062] [MGI Ref ID J:107047]
Holz A; Brett K; Oldstone MB. 2001. Constitutive beta cell expression of IL-12 does not perturb self-tolerance but intensifies established autoimmune diabetes. J Clin Invest 108(12):1749-58. [PubMed: 11748258] [MGI Ref ID J:134571]
Homann D; Holz A; Bot A; Coon B; Wolfe T; Petersen J; Dyrberg TP; Grusby MJ; von Herrath MG. 1999. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 11(4):463-72. [PubMed: 10549628] [MGI Ref ID J:96857]
Homann D; Jahreis A; Wolfe T; Hughes A; Coon B; van Stipdonk MJ; Prilliman KR; Schoenberger SP; von Herrath MG. 2002. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity 16(3):403-15. [PubMed: 11911825] [MGI Ref ID J:96858]
Juedes AE; Rodrigo E; Togher L; Glimcher LH; von Herrath MG. 2004. T-bet controls autoaggressive CD8 lymphocyte responses in type 1 diabetes. J Exp Med 199(8):1153-62. [PubMed: 15096540] [MGI Ref ID J:121024]
Lang PA; Cervantes-Barragan L; Verschoor A; Navarini AA; Recher M; Pellegrini M; Flatz L; Bergthaler A; Honda K; Ludewig B; Ohashi PS; Lang KS. 2009. Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. Blood 113(5):1045-52. [PubMed: 18971424] [MGI Ref ID J:145035]
Martinic MM; Juedes AE; Bresson D; Homann D; Skak K; Huber C; Ling E; Ejrnaes M; Wolfe T; Togher L; Christen U; von Herrath MG. 2007. Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice. Diabetes 56(4):1059-68. [PubMed: 17395746] [MGI Ref ID J:122080]
Muchamuel T; Basler M; Aujay MA; Suzuki E; Kalim KW; Lauer C; Sylvain C; Ring ER; Shields J; Jiang J; Shwonek P; Parlati F; Demo SD; Bennett MK; Kirk CJ; Groettrup M. 2009. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15(7):781-7. [PubMed: 19525961] [MGI Ref ID J:151526]
Rhode A; Pauza ME; Barral AM; Rodrigo E; Oldstone MB; von Herrath MG; Christen U. 2005. Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 175(6):3516-24. [PubMed: 16148094] [MGI Ref ID J:116715]
Van Belle TL; Esplugues E; Liao J; Juntti T; Flavell RA; von Herrath MG. 2011. Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model. J Immunol 187(6):2915-22. [PubMed: 21832162] [MGI Ref ID J:179258]
von Herrath MG; Dockter J; Oldstone MB. 1994. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1(3):231-42. [PubMed: 7889411] [MGI Ref ID J:81287]
von Herrath MG; Oldstone MB. 1997. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 185(3):531-9. [PubMed: 9053453] [MGI Ref ID J:96856]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.Colony Maintenance
Mating System +/+ sibling x Hemizygote (Female x Male) 24-APR-08 Diet Information LabDiet® 5K52/5K67
Pricing and Purchasing
Pricing, Supply Level & Notes, Controls
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2250.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2925.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
|
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
General Supply Notes
- This strain is included in the Type 1 Diabetes Repository collection.
- Genomic DNA is available for this strain from the Mouse DNA Resource.
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries regarding Terms of UseContracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.